Publication | Open Access
Combined targeting EGFR and SRC as a potential novel therapeutic approach for the treatment of triple negative breast cancer
33
Citations
50
References
2020
Year
We demonstrate that afatinib combined with dasatinib has potential clinical activity in TNBC but warrants further preclinical investigation.
| Year | Citations | |
|---|---|---|
Page 1
Page 1